Pelthos Therapeutics Files 8-K on Shareholder Votes

Ticker: PTHS · Form: 8-K · Filed: 2025-12-17T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing-update

TL;DR

Pelthos Therapeutics filed an 8-K on 12/17/25 regarding shareholder votes. Big decisions ahead.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K on December 17, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Channel Therapeutics Corp and Chromocell Therapeutics Corp, is incorporated in Nevada and operates in the biological products sector.

Why It Matters

This filing indicates important corporate actions or decisions are being made that could affect shareholders and the company's strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an event that inherently increases risk.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Pelthos Therapeutics Inc. security holders?

The filing states that it is a report on 'Submission of Matters to a Vote of Security Holders', but the specific details of the matters voted upon are not included in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported is December 17, 2025, which is also the date of the report.

What is the principal executive office address for Pelthos Therapeutics Inc.?

The principal executive office is located at 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703.

What were the previous names of Pelthos Therapeutics Inc.?

Pelthos Therapeutics Inc. was formerly known as Channel Therapeutics Corp and prior to that, Chromocell Therapeutics Corp.

In which state is Pelthos Therapeutics Inc. incorporated?

Pelthos Therapeutics Inc. is incorporated in Nevada.

From the Filing

0001753926-25-001906.txt : 20251217 0001753926-25-001906.hdr.sgml : 20251217 20251217161556 ACCESSION NUMBER: 0001753926-25-001906 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251217 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20251217 DATE AS OF CHANGE: 20251217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251579474 BUSINESS ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-908-2422 MAIL ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g085048_8k.htm 8-K false 0001919246 0001919246 2025-12-17 2025-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 17, 2025   Pelthos Therapeutics Inc. (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (919) 908-2400      (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 5.07 Submission of Matters to a Vote of Security Holders.   On December 17, 2025, Pelthos Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the three proposals that were voted on at the Annual Meeting and the stockholder vote

View on Read The Filing